October 24, 2016 4:29 PM ET


Company Overview of Taligen Therapeutics, Inc.

Company Overview

As of January 28, 2011, Taligen Therapeutics, Inc. was acquired by Alexion Pharmaceuticals, Inc. Taligen Therapeutics, Inc., a development stage biotechnology company, focuses on the treatment of inflammatory diseases. It employs novel technologies designed to modulate and regulate activation of the complement system for the treatment of asthma, macular degeneration, and immune kidney diseases. The company offers TA106, which is a monoclonal antibody developed as an inhaled product candidate for the treatment of asthma; and TT30, which delivers complement inhibitors, such as Factor H to sites, where complement activation occurs and drives inflammation. Taligen Therapeutics, Inc. was incorpor...

245 First Street

18th Floor

Suite 1830

Cambridge, MA 02142

United States

Founded in 2004





Key Executives for Taligen Therapeutics, Inc.

Taligen Therapeutics, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Taligen Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.